8-K: UroGen Pharma Reports Positive UGN-102 Trial Data and Q2 2024 Financial Results, Nears NDA Submission

UroGen Pharma is ahead of schedule for its UGN-102 NDA submission, reporting strong 12-month duration of response data and Q2 2024 financial results.

Summary

• UroGen Pharma announced its second quarter 2024 financial results and provided an update on its business activities.
• The company is prioritizing the submission of a New Drug Application (NDA) for UGN-102, a potential treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
• The Phase 3 ENVISION trial for UGN-102 showed an 82.3% duration of response at 12 months in patients who achieved a complete response at three months.
• UroGen reported JELMYTO net product revenues of $21.8 million for Q2 2024, compared to $21.1 million in Q2 2023.
• The company ended Q2 2024 with $241.3 million in cash, cash equivalents, and marketable securities.
• UroGen completed a public offering of ordinary shares and pre-funded warrants, raising approximately $107.5 million in gross proceeds, with an additional $16.1 million from the underwriter's option exercise.
• The company's net loss for Q2 2024 was $33.4 million, or ($0.91) per share, compared to a net loss of $24.1 million, or ($1.03) per share, in Q2 2023.
• UroGen is developing next-generation mitomycin-based formulations, UGN-103 and UGN-104, for UGN-102 and JELMYTO, respectively.
• The company expects to be towards the higher end of its full-year 2024 operating expense guidance and sees a path toward the lower end of its full-year 2024 JELMYTO revenue guidance.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical trial results for UGN-102 and a solid cash position, although there are some concerns about increasing operating expenses and a potential slowdown in JELMYTO revenue growth. The successful capital raise is also a positive.

Positives

• The 12-month duration of response data for UGN-102 is very strong at 82.3%, indicating a potentially effective treatment for LG-IR-NMIBC.
• JELMYTO continues to generate solid revenue, with $21.8 million in Q2 2024.
• The company has a strong cash position of $241.3 million, providing financial stability.
• The successful public offering and underwriter option exercise raised significant capital.
• The development of UGN-103 and UGN-104 could provide manufacturing efficiencies and additional intellectual property protection.
• The company is ahead of schedule for the UGN-102 NDA submission.

Negatives

• The company reported a net loss of $33.4 million in Q2 2024, which is higher than the $24.1 million loss in Q2 2023.
• Operating expenses are expected to be towards the higher end of the full-year guidance.
• The company sees a path toward the lower end of its full-year 2024 JELMYTO revenue guidance.

Risks

• The NDA for UGN-102 may not be accepted by the FDA, or if accepted, may not receive priority review or approval.
• Clinical trials for UGN-103 and UGN-104 may not be successful.
• The company may face competition in the urothelial cancer market.
• The company's financial condition may require additional capital in the future.
• The company's RTGel technology may not perform as expected.

Future Outlook

UroGen anticipates completing its NDA submission for UGN-102 in the very near term with a potential FDA decision as early as the first quarter of 2025, assuming priority review. The company expects to be towards the higher end of its full-year 2024 operating expense guidance and sees a path toward the lower end of its full-year 2024 JELMYTO revenue guidance. UroGen plans to initiate a Phase 3 study of UGN-104 in LG-UTUC early next year.

Management Comments

• Liz Barrett, President and Chief Executive Officer of UroGen, stated that the company's immediate priority is completing the submission of a New Drug Application for UGN-102.
• Ms. Barrett believes UGN-102 has the potential to be a practice-changing therapy for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
• Ms. Barrett estimates that approximately 82,000 patients suffering from this highly recurrent disease each year may benefit from an innovative treatment, creating an estimated five-billion-dollar market opportunity.

Industry Context

This announcement is significant in the context of the urothelial cancer treatment landscape, as UGN-102 has the potential to be the first FDA-approved medicine for low-grade intermediate-risk non-muscle invasive bladder cancer. The company's focus on developing innovative solutions for urothelial cancers aligns with the growing need for effective treatments in this area.

Comparison to Industry Standards

• The 82.3% 12-month duration of response for UGN-102 is very strong compared to existing treatments for LG-IR-NMIBC, which often have high recurrence rates.
• JELMYTO's revenue of $21.8 million in Q2 2024 is a solid performance, but the company's guidance suggests a potential slowdown in growth for the remainder of the year.
• The company's cash position of $241.3 million is robust compared to many other biotech companies at a similar stage of development, providing a strong financial foundation for future growth.
• The development of UGN-103 and UGN-104, next-generation mitomycin-based formulations, is a positive step, as it addresses potential manufacturing and intellectual property challenges, similar to other companies in the pharmaceutical space that are looking to improve existing products.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results, the progress of UGN-102, and the capital raise.
• Employees will be impacted by the company's growth and the potential launch of new products.
• Patients with LG-IR-NMIBC and LG-UTUC may benefit from the development of new treatment options.
• Creditors will be impacted by the company's financial performance and debt obligations.

Next Steps

• UroGen plans to complete the NDA submission for UGN-102 in the very near term.
• The company will prepare for the potential launch of UGN-102, if approved.
• UroGen plans to initiate a Phase 3 study of UGN-104 in LG-UTUC early next year.

Key Dates

Keywords

UGN-102, JELMYTO, LG-IR-NMIBC, LG-UTUC, mitomycin, NDA, clinical trial, urothelial cancer, RTGel, FDA